Nuvalent CFO sells 25,130 shares after option exercise

Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock.

Rhea-AI Filing Summary

Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock. On March 24, 2026, she exercised stock options for 11,430 shares of Class A Common Stock at $1.08 per share and sold 11,430 shares that day in open-market trades at weighted-average prices in the mid-$90s. She then sold an additional 13,700 shares on March 25, 2026 at a weighted-average price of $100.16 per share in open-market transactions. All sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. After these transactions, she directly holds 85,533 shares of Nuvalent Class A Common Stock.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Balcom Alexandra

Role Chief Financial Officer

Sold 25,130 shs ($2.47M)

Approx. gross sale proceeds $2.47M

Approx. exercise cost $12K

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	13,700	$100.16	$1.37M
Exercise	Stock Option (Right to Buy)	11,430	$0.00	$0.00
Exercise	Class A Common Stock	11,430	$1.08	$12K
Sale	Class A Common Stock	2,599	$95.03	$247K
Sale	Class A Common Stock	7,671	$95.88	$735K
Sale	Class A Common Stock	1,160	$96.50	$112K

Holdings After Transaction: Stock Option (Right to Buy) — 150,226 contracts (Direct); Class A Common Stock — 85,533 shares (Direct)

Footnotes (6)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.34 to $95.33, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) of this Form 4.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.35 to $96.34, inclusive.
4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.35 to $96.72, inclusive.
5. F5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.61, inclusive.
6. F6. The shares underlying this option are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nuvalent (NUVL) report for CFO Alexandra Balcom?

Nuvalent reported that CFO Alexandra Balcom exercised stock options for 11,430 shares and sold a total of 25,130 Class A Common shares in open-market transactions. These trades occurred on March 24 and March 25, 2026, as disclosed in the Form 4 filing.

How many Nuvalent (NUVL) shares did the CFO sell and at what prices?

The CFO sold 25,130 Nuvalent Class A Common shares in total. Weighted-average sale prices were in the mid-$90s on March 24, 2026, and $100.16 per share on March 25, 2026, through open-market or private transactions described in the Form 4.

Did Nuvalent (NUVL) CFO Alexandra Balcom exercise stock options in this Form 4?

Yes. Alexandra Balcom exercised a stock option covering 11,430 shares of Nuvalent Class A Common Stock at an exercise price of $1.08 per share. The underlying option was fully vested, and the exercised shares were then sold in open-market transactions on March 24, 2026.

How many Nuvalent (NUVL) shares does the CFO hold after these transactions?

Following the reported transactions, CFO Alexandra Balcom directly holds 85,533 shares of Nuvalent Class A Common Stock. This post-transaction holding reflects the net result after exercising 11,430 options and selling a total of 25,130 shares across March 24 and March 25, 2026.

Were Nuvalent (NUVL) CFO sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Alexandra Balcom on December 23, 2025. Such plans pre-schedule trades, indicating the timing was set in advance rather than decided spontaneously.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/26/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/24/2026		M(1)		11,430	A	$1.08	110,663	D
Class A Common Stock	03/24/2026		S(1)		2,599	D	$95.03(2)	108,064	D
Class A Common Stock	03/24/2026		S(1)		7,671	D	$95.88(3)	100,393	D
Class A Common Stock	03/24/2026		S(1)		1,160	D	$96.5(4)	99,233	D
Class A Common Stock	03/25/2026		S(1)		13,700	D	$100.16(5)	85,533	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.08	03/24/2026		M(1)			11,430	(6)	02/16/2031	Class A Common Stock	11,430	$0.00	150,226	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.34 to $95.33, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.35 to $96.34, inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.35 to $96.72, inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.61, inclusive.

6. The shares underlying this option are fully vested.

	/s/ Nathan N. McConarty, attorney-in-fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)